ペプチドリーム(株)の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|
東証PRM | 医薬品 | 4587/ - | - |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|
2015/01/30 | 日証協 | 348,414株 | -2.46% | 49,249株 | +247.73% | 278,811株 | -4.32% | 79,114株 | +469.17% |
2015/01/23 | 日証協 | 357,214株 | -13.11% | 14,163株 | +53.85% | 291,397株 | -10.7% | 13,900株 | -88.33% |
2015/01/16 | 日証協 | 411,096株 | +0.98% | 9,206株 | -26.94% | 326,305株 | +8.98% | 119,100株 | +543.75% |
2015/01/09 | 日証協 | 407,096株 | -0.05% | 12,600株 | +215% | 299,404株 | -1.28% | 18,501株 | +175.15% |
2014/12/30 | 日証協 | 407,296株 | +5.82% | 4,000株 | -86.67% | 303,294株 | -5.72% | 6,724株 | -56.35% |
2014/12/26 | 日証協 | 384,896株 | -7.5% | 30,000株 | +195.36% | 321,711株 | -5.8% | 15,403株 | -29.99% |
2014/12/19 | 日証協 | 416,096株 | -12.24% | 10,157株 | -61.38% | 341,516株 | -3.17% | 22,001株 | -33.79% |
2014/12/12 | 日証協 | 474,139株 | -0.47% | 26,300株 | -17.55% | 352,705株 | -0.18% | 33,230株 | +262.38% |
2014/12/05 | 日証協 | 476,400株 | -4.89% | 31,900株 | +459.65% | 353,357株 | -10.95% | 9,170株 | -26.05% |
2014/11/28 | 日証協 | 500,900株 | -4.12% | 5,700株 | -87.53% | 396,797株 | -5.03% | 12,400株 | +129.54% |
2014/11/21 | 日証協 | 522,400株 | -5.22% | 45,700株 | -17.33% | 417,797株 | +6.1% | 5,402株 | -92.87% |
2014/11/14 | 日証協 | 551,184株 | +0.22% | 55,283株 | -26.79% | 393,763株 | -8.55% | 75,720株 | +12.5% |
2014/11/07 | 日証協 | 550,000株 | +6.97% | 75,508株 | +63.44% | 430,562株 | +12.84% | 67,308株 | +137% |
2014/10/31 | 日証協 | 514,184株 | +4.73% | 46,200株 | +10% | 381,563株 | +6.33% | 28,400株 | -24.06% |
2014/10/24 | 日証協 | 490,984株 | -4.36% | 42,000株 | -30.81% | 358,864株 | -5.5% | 37,400株 | -36.29% |
2014/10/17 | 日証協 | 513,384株 | -13.31% | 60,700株 | -47.13% | 379,764株 | -11.01% | 58,700株 | -50.59% |
2014/10/10 | 日証協 | 592,184株 | +16.85% | 114,800株 | +59.34% | 426,766株 | +23.79% | 118,802株 | +386.38% |
2014/10/03 | 日証協 | 506,784株 | -6.92% | 72,047株 | +613.34% | 344,762株 | +2.34% | 24,426株 | +396.46% |
2014/09/26 | 日証協 | 544,437株 | +0.37% | 10,100株 | -80.84% | 336,870株 | -11.18% | 4,920株 | -83.82% |
※株式分割は考慮していませんのでご注意ください。
Page Top